Interview: Summit Hits The Heights With Billionaire Backing
Executive Summary
Ex-Pharmacyclics CEO Bob Duggan is to invest $25m into Summit Therapeutics, taking a near 49% stake in the UK firm and helping it fund Phase III trials for the Oxford-based firm's lead antibiotic candidate ridinilazole.
You may also be interested in...
A Call To Action On Antibiotic Development
Recent comments by US FDA’s top infectious disease review manager about the need for new ideas to incentive development of antibiotics should be a call to action for biopharma companies and patient advocates who do not normally consider infectious disease as part of the portfolio.
'Slow Money As Bad As No Money' – SMEs Struggle For Superbug Funds
The key to getting funding for small biotechs which focus on tackling antimicrobial resistance is to get private investors interested to top up 'push' incentives from the likes of CARB-X, the AMR Centre's Peter Jackson tells Scrip.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.